Skip to content

Effect of M-Health on secondary prevention of coronary artery disease patients

The effectiveness of applying Mobile-Health Technology to manage modifiable risk factors of coronary artery disease for secondary prevention: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221016056204N1
Enrollment
1544
Registered
2023-03-12
Start date
2022-11-22
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery disease. 125.0

Interventions

Intervention 1: Intervention group: Installation and applying mobile-health technology (Green Heart application) on the smartphone plus routine care. The Green Heart application contains sections for

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: History of CAD defined as history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, coronary angiography confirming stenosis>50% in at least one of the major epicardial coronary arteries or their main branches. Having at least one uncontrolled risk factor including: uncontrolled hypertension, uncontrolled dyslipidemia and current cigarette smoking for =12 months. Aged between 25 to 75 years Inclination to staying in study for two years Having and ability of using smart phone by the participant or one of his/her trustworthy relatives who lives near him/her Willing to control the risk factors using App Provides informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Mental retardation Individuals with prohibitive morbidity that requires close face-to-face monitoring. End stage chronic disease such as: hepatic and/or renal failure, heart failure, active cancer

Design outcomes

Primary

MeasureTime frame
Smoking Cessation. Timepoint: Three months post-randomization. Method of measurement: Self-report for quitting smoking.;Blood pressure control to less than 130/80 mm Hg. Timepoint: Three months post-randomization. Method of measurement: Sphygmomanometer/Blood pressure measurement by the physician in the clinic.;Dyslipidemia control with the target of low-density lipoprotein cholesterol (LDL-C) less than 55 mg/dL. Timepoint: Three months post-randomization. Method of measurement: Lab test to measure low-density lipoprotein cholesterol.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojgan Ghavami

Tehran University of Medical Sciences

m_ghavami@razi.tums.ac.ir+98 21 6651 3375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026